|
Denali/Sirion deal to get AAVs across the BBB
|
2
|
BIOASIS TECHNOLOGIES INC
|
Jan 09, 2019 01:34PM
|
|
DESIGN AND CHARACTERIZATION OF NOVEL COVALENT BROMODOMAIN AND EXTRA-TERMINAL DOMAIN (BET) INHIBITORS TARGETING A METHIONINE
|
7
|
Zenith Epigenetics
|
Sep 04, 2018 10:23AM
|
|
Diabetes Awareness Month and World Diabetes Day
|
2
|
Resverlogix Corp.
|
Nov 04, 2017 08:05AM
|
|
Do we have a pipeline and is it promising?
|
3
|
Resverlogix Corp.
|
Apr 05, 2017 11:28AM
|
|
Don continuing to build relations with Chinese investors
|
5
|
Resverlogix Corp.
|
Jun 12, 2015 01:42PM
|
|
Dosing schedule for ZEN-3694
|
6
|
Zenith Epigenetics
|
Jul 13, 2016 05:10PM
|
|
Dr. Kausik Ray will deliver the AHA Late Breaking Presentation on BETonMACE
|
12
|
Resverlogix Corp.
|
Nov 03, 2019 09:10AM
|
|
Dr. Mark Day interview with Proactive Investors at BIO CEO
|
1
|
BIOASIS TECHNOLOGIES INC
|
Feb 12, 2019 07:47AM
|
|
Draft Checklist for Management
|
|
Resverlogix Corp.
|
Jul 25, 2016 11:51AM
|
|
EAS tweet
|
7
|
Resverlogix Corp.
|
Feb 25, 2019 11:48AM
|
|
EASD 2019 Sept 16-20, 2019
|
4
|
Resverlogix Corp.
|
Jul 18, 2019 04:18PM
|
|
Effect of BoM dropouts on trial
|
4
|
Resverlogix Corp.
|
Apr 27, 2018 10:52AM
|
|
Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism
|
4
|
Resverlogix Corp.
|
May 24, 2016 02:58PM
|
|
Encouraging H1 2017....keep up the good work team Resverlogix
|
6
|
Resverlogix Corp.
|
Jun 04, 2017 03:52PM
|
|
Endocrine News
|
8
|
Resverlogix Corp.
|
Jun 01, 2017 10:40PM
|
|
Endpoint News BET Inhibitors
|
6
|
Zenith Epigenetics
|
Mar 27, 2018 08:21PM
|
|
Enforcement of Agoracom Rules - Preclin
|
9
|
Resverlogix Corp.
|
May 26, 2019 11:38PM
|
|
Enzalutamide effective in non-metastatic prostate cancer
|
7
|
Zenith Epigenetics
|
Jun 28, 2018 04:26PM
|
|
Enzalutamide/Abirate... Resistance and mCRPC
|
4
|
Zenith Epigenetics
|
Dec 22, 2016 04:48PM
|
|
Epigenetic drugs, cardiometabolic disease and atherosclerosis
|
3
|
Resverlogix Corp.
|
Oct 16, 2018 04:45PM
|
